tirzepatide heart failure trial SUMMIT: Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity Tirzepatide Improves HFpEF Symptoms and
Description
Your healthcare provider can guide you on any necessary medication adjustments
Time in range (TIR) increased from 56.9% at baseline to 88.9%, 76.2% and 71.7% with CagriSema, semaglutide and cagrilintide, respectively [124]
J.AlbrechtsenN
They provide longer-lasting effects but can take longer to kick in , making it important to dose them carefully
Of these, 92/129 subjects achieved a mW of 83.2 14.0 kg and mBMI of 30.6 4.4 kg/m 2 , with a mW and mBMI reduction respectively of 15.9 11.4 kg ( 15.0 8.7%) and 5.8 3.7 kg/m 2 (Fig
